Renovaro Biosciences Inc Total Liabilities
Renovaro Biosciences Inc total liabilities. Based on the latest financial reports, Renovaro Biosciences Inc (RENB) has total liabilities worth $29.58 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check RENB financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Renovaro Biosciences Inc (2011–2025)
Total liabilities of Renovaro Biosciences Inc from 2011 to 2025. This chart illustrates how Renovaro Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore RENB long-term investments to assets to see how much of total assets are deployed in long-term investments.
Renovaro Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Renovaro Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Minesto AB
ST:MINEST
|
Sweden | Skr22.24 Million |
|
Thai Film Industries Public Company Limited
BK:TFI
|
Thailand | ฿797.57 Million |
|
Hansol Pns
KO:010420
|
Korea | ₩65.03 Billion |
|
Derwent London PLC
LSE:DLN
|
UK | GBX1.70 Billion |
|
Briacell Therapeutics Corp
NASDAQ:BCTX
|
USA | $3.66 Million |
|
Thai O.P.P. Public Company Limited
BK:TOPP
|
Thailand | ฿350.88 Million |
|
PM Thoresen Asia Holdings PCL
BK:PMTA
|
Thailand | ฿1.06 Billion |
|
CompuLab Ltd
TA:CLAB
|
Israel | ILA24.65 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Renovaro Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Renovaro Biosciences Inc (RENB) total assets.
Liquidity & Leverage Metrics
Renovaro Biosciences Inc Total Liabilities Ratios Explained
Renovaro Biosciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Renovaro Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Renovaro Biosciences Inc (2011–2025)
The table below shows the annual total liabilities of Renovaro Biosciences Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | $31.15 Million | 0.00% |
| 2024-06-30 | $31.15 Million | +164.03% |
| 2023-06-30 | $11.80 Million | -1.79% |
| 2022-06-30 | $12.01 Million | -19.60% |
| 2021-06-30 | $14.94 Million | +26.31% |
| 2020-06-30 | $11.83 Million | +74.55% |
| 2019-06-30 | $6.78 Million | -71.48% |
| 2018-06-30 | $23.76 Million | +694.96% |
| 2017-06-30 | $2.99 Million | +98.21% |
| 2016-06-30 | $1.51 Million | -14.19% |
| 2015-06-30 | $1.76 Million | -16.30% |
| 2014-06-30 | $2.10 Million | +2848.11% |
| 2013-06-30 | $71.23K | +161.55% |
| 2012-06-30 | $27.23K | +211.79% |
| 2011-06-30 | $8.73K | -- |
About Renovaro Biosciences Inc
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors… Read more